1. Home
  2. OLP vs MLYS Comparison

OLP vs MLYS Comparison

Compare OLP & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo One Liberty Properties Inc.

OLP

One Liberty Properties Inc.

HOLD

Current Price

$20.35

Market Cap

478.2M

Sector

Real Estate

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$35.50

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OLP
MLYS
Founded
1982
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
478.2M
3.1B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
OLP
MLYS
Price
$20.35
$35.50
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$47.33
AVG Volume (30 Days)
107.8K
1.5M
Earning Date
11-06-2025
02-11-2026
Dividend Yield
8.85%
N/A
EPS Growth
N/A
N/A
EPS
1.54
N/A
Revenue
$97,423,000.00
N/A
Revenue This Year
$7.95
N/A
Revenue Next Year
$6.06
N/A
P/E Ratio
$13.23
N/A
Revenue Growth
9.29
N/A
52 Week Low
$19.62
$8.24
52 Week High
$28.36
$47.65

Technical Indicators

Market Signals
Indicator
OLP
MLYS
Relative Strength Index (RSI) 45.89 36.08
Support Level $19.86 $36.50
Resistance Level $21.66 $37.75
Average True Range (ATR) 0.35 1.65
MACD -0.07 0.01
Stochastic Oscillator 28.31 10.70

Price Performance

Historical Comparison
OLP
MLYS

About OLP One Liberty Properties Inc.

One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: